Vizimpro Interactions
There are 109 drugs known to interact with Vizimpro (dacomitinib), along with 2 disease interactions. Of the total drug interactions, 24 are major, 83 are moderate, and 2 are minor.
- View all 109 medications that may interact with Vizimpro
- View Vizimpro disease interactions (2)
Most frequently checked interactions
View interaction reports for Vizimpro (dacomitinib) and the medicines listed below.
- acetaminophen
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Advair HFA (fluticasone / salmeterol)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- ambrisentan
- Amitiza (lubiprostone)
- Amondys 45 (casimersen)
- apremilast
- Astelin (azelastine nasal)
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- azelastine nasal
- Azo Urinary Pain Relief (phenazopyridine)
- Bafiertam (monomethyl fumarate)
- Benlysta (belimumab)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Bimzelx (bimekizumab)
- Blincyto (blinatumomab)
- bosentan
- Braftovi (encorafenib)
- Breyanzi (lisocabtagene maraleucel)
- Brilinta (ticagrelor)
- Brineura (cerliponase alfa)
- Briumvi (ublituximab)
- Brukinsa (zanubrutinib)
- BuSpar (buspirone)
Vizimpro disease interactions
There are 2 disease interactions with Vizimpro (dacomitinib) which include:
Report options
QR code containing a link to this page
More about Vizimpro (dacomitinib)
- Vizimpro consumer information
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: EGFR inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
